ICH Q3E on Extractables and Leachables: Preparing for the First Harmonised E&L Guideline

Extractables and leachables have long been assessed through a patchwork of regional guidance, pharmacopoeial chapters and industry practice. ICH Q3E is set to become the first harmonised guideline on the topic. The draft reached Step 2 in August 2025, regional consultations have closed, and the ICH work plan targets final adoption in 2027. Companies developing parenteral, inhaled and other higher-risk products should start aligning their packaging and process-equipment strategies now.

Where Q3E stands

The ICH Management Committee endorsed work on extractables and leachables in 2020. The draft guideline was endorsed at Step 2 in August 2025 and released for public consultation in the ICH regions. According to the Expert Working Group’s 2026 work plan, comments are being consolidated, a revised draft is planned for early 2027 and Step 4 sign-off is targeted for mid-2027. Alongside the guideline, a threshold project is developing permitted daily exposure monographs for commonly observed leachables.

What the guideline addresses

  • Scope: leachables that can migrate into a drug product from container closure systems and from manufacturing components such as tubing, filters and single-use systems.
  • Risk-based approach: the extent of extractables and leachables work depends on the route of administration, the dosage form, the duration of contact and the conditions of use.
  • Safety assessment: leachables are evaluated against toxicological thresholds and, where available, compound-specific limits.
  • Lifecycle: changes to materials, suppliers or processes can trigger a reassessment.

Until the final text is adopted, the details of thresholds and study expectations may still change, so companies should treat the draft as direction rather than requirement.

Where it touches the dossier and GMP

  • Container closure information in Module 3.2.P.7 and the related justification in Module 3.2.P.2
  • Supplier qualification and change notification for packaging and single-use components
  • Change control and regulatory impact assessment when a material or supplier changes
  • Existing EU expectations for plastic immediate packaging, which remain in force in the meantime

Practical preparation

  • Inventory the product-contact materials across your portfolio and rank them by risk
  • Review whether existing extractables studies and leachables data would stand up to a harmonised, risk-based standard
  • Build E&L considerations into supplier agreements so that material changes are notified in time
  • Follow the final Q3E text and EMA and FDA implementation dates before re-running studies

How PQRA helps

PQRA supports CMC teams with Module 3 gap analyses, container closure documentation, supplier qualification and change control, and helps companies assess the regulatory impact of packaging and material changes across EU and national procedures.

Talk to PQRA about your E&L strategy

CATEGORIES:

Uncategorized

Tags:

No responses yet

Αφήστε μια απάντηση

Η ηλ. διεύθυνση σας δεν δημοσιεύεται. Τα υποχρεωτικά πεδία σημειώνονται με *